
    
      Subjects received subcutaneous methylnaltrexone (also referred to as MOA-728 or MNTX) or
      placebo every other day beginning on Day 1 up to a maximum of 7 doses during the 2-week
      double-blind period.

      Inclusion criteria for this study included subjects with advanced illness or subjects with
      chronic nonmalignant pain. The actual study population included only subjects with
      cancer-related advanced illness.

      All subjects who completed the double-blind treatment phase of this study could elect to
      receive methylnaltrexone during a 12-week open-label extension study, provided eligibility
      criteria were met. Subjects who did not continue in the open-label extension study had a
      follow-up visit 2 weeks after their last dose of test article.
    
  